 |
| Click for printable flyer |
Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate with Gastrointestinal Disturbances Following Therapy Initiation?
Description
The primary objective of this pilot study is to determine whether a measureable change in bacteria represented in the gut takes place following the initiation of dimethyl fumarate, also known as Tecfidera. This study will assess whether a measured change in gut bacterial flora corresponds to the risk of developing gastrointestinal disturbances and of changes in mood state.
There are 2 in-clinic study visits and 3 telephone-only study visits required, taking place over a 24-week period.
Currently enrolling
Who may be eligible to participate?
Individuals with a confirmed diagnosis of a relapsing form of MS. No prior treatment with Tecfidera, or prior clinical trial related dimethyl fumarate therapy. Age 18 and over.
Individuals with a confirmed diagnosis of a relapsing form of MS. No prior treatment with Tecfidera, or prior clinical trial related dimethyl fumarate therapy. Age 18 and over.
Investigator: Virginia Simnad, M.D.
For More Information: Shalom Kilcup –425.899.5369 SEKilcup@evergreenhealth.com
No comments:
Post a Comment